Investment case
Roche Holding AG (ADR)
RHHBY · 9 developments mapped · last assessed 2026-09-23
Market Ontology has mapped 9 macro, policy, and market developments to Roche Holding AG (ADR) since 2026-09-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for RHHBY yet, so no modelled value is shown. The RHHBY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run RHHBY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
Successful advancement of a high-potential drug candidate into Phase III, significantly increasing the probability of future market entry and substantial revenue generation in the lucrative obesity/diabetes market.
· Moves probability of regulatory approval for enicepatide, peak sales estimates for enicepatide, future r&d efficiency
- Main threat
FDA Approves Isembyld for Spinal Muscular Atrophy
Increased competition in the SMA treatment market, potential erosion of market share for existing therapies.
· Moves peak sales estimates for evrysdi, market share projections for evrysdi
- Open question
Roche to Acquire Ionis Pharmaceuticals, Inc.
Acquisition cost and potential dilution vs. pipeline enhancement and future revenue growth. Positive clinical trial results for a key pipeline asset.
· Moves synergy assumptions, cost of capital, future growth rates
What changed, by assumption
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide
- 2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.
- 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
- 2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophy
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | mixed | 1-3m | 0.60 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide | Bullish | 1-5y | 0.80 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide | Bullish | 1-5y | 0.80 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Bearish | 1-3m | 0.50 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Bearish | 1-3m | 0.50 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | mixed | 3-12m | 0.30 |